MOVING AHEAD REQUIRES A SURE PATH FORWARD
Trials are inherently risky, and every detail matters. We spot risks before they become problems to help you avoid costly delays through an array of solutions that provide confidence at every turn.
ENHANCE TRIAL OVERSIGHT
Run more efficient trials by unlocking hidden insights
enable site optimization
Generate high-quality data by optimizing site selection and performance
increase patient engagement
Equip patients with the tools to take control of their health
ensure safety and measure efficacy
By driving high-quality data
THE ERT EXPERT PLATFORM
The ERT EXPERT® platform is the underlying proprietary technology that powers all ERT solutions. Improve trial visibility and performance and reduce time-to-market with confidence, agility and acceleration.
MINIMIZe RISK AND UNCERTAINTY
We enable the flexibility and adaptability you need to accelerate through hurdles for faster speed to market. Here’s how:
Every trial runs into unexpected challenges. With more than 13,000 trials under our belt, we’ve seen most of them before and have the expertise to put your trial back on course.
We’ll protect the success of your trial before there’s ever an issue, with near real-time access to study, program and enterprise-level performance.
NEWS & EVENTS
July 26, 2018
Four Steps to Implementing Risk-based Quality Management
Learn how a Risk-based Quality Management (RBQM) approach to trial management ─ including technology that integrates data from multiple sources for real-time decision making ─ helps sponsors and CROs mitigate clinical trial risks before they become costly problems.
July 30, 2018
Putting Patients First – Building Adaptive Digital Health Programs
This article reviews how the ERT/Foundry3 collaboration is delivering rich, adaptive digital health programs ─ based on substantiated patient needs ─ to help patients better manage their conditions and ultimately improve health outcomes.
August 10, 2018
Why Early Phase Cardiac Safety Assessment Makes Good Business Sense
Learn how determining the cardiac safety profile of your compound by assessing QT during routine Phase I studies enables you to make go/no-go decisions sooner, better prioritize your drug development pipeline, and appropriately resource or refocus programs exhibiting potential cardiac safety issues.